The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy

Dupilumab is a biological agent that addresses the pathophysiology of atopic dermatitis (AD) by modulating signaling of interleukin-4 and interleukin-13, the primary interleukins involved in the type 2 helper T-cell response. Dupilumab was approved by the US Food and Drug Administration on March 28, 2017, for moderate-to-severe AD not adequately controlled with topical prescription therapy in adults.